01-05-2022 | Catastrophic Antiphospholipid Syndrome | Case report
Eculizumab/dalteparin-sodium
Staphylococcus aureus infection and granulocytopenia following an off-label use: 3 case reports
Published in: Reactions Weekly | Issue 1/2022
Login to get accessExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event